+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

A

Actively Recruiting

Healthy Volunteer

Researchers are conducting an observational registry to collect standardized data from adult patients receiving routine oncology care at participating cancer centers. The study aims to gather detailed information such as baseline patient characteristics, treatments administered, and outcomes to support research and improve clinical trial participation. Patient surveys are also included to enrich the data collected. No treatments or interventions are given as part of this registry. Instead, data is gathered from patients receiving their usual cancer care. This open-ended registry will continuously collect and analyze information over time to better understand treatment patterns, safety, and effectiveness. Participants will provide informed consent and contribute data through their regular care visits and surveys. Researchers will monitor treatment effectiveness mainly by tracking the time until treatment discontinuation. The registry will regularly analyze and present the data collected. Participation may last as long as the patient is receiving treatment and contributing data, with long-term follow-up possible.

Age: 18Years - 120YearsAll Genders
7 locations
P

Actively Recruiting

Researchers are studying patients with advanced or metastatic non-small cell lung cancer NSCLC to create control groups using current and future patient data. The study aims to generate precision external control arms by observing different patient cohorts categorized by specific genetic mutations and treatment lines. This observational study helps understand treatment responses in real-world settings without assigning specific therapies. Participants are grouped based on their treatment regimens and genetic profiles, such as those starting first-line immune checkpoint inhibitor therapies, patients with actionable EGFR mutations, KRAS mutations, or varying PD-L1 expression levels. The study observes patients receiving standard therapies, such as platinum doublets, targeted agents like osimertinib or lazertinib, or other recommended treatments across different lines of therapy. The study spans from January 2026 to April 2029. During the study, participants response rates to therapies will be assessed, focusing on Objective Response Rate ORR in metastatic NSCLC patients treated in second or third line settings. Secondary measures include progression-free survival, overall survival, and time to next treatment. Participants will be monitored through clinical evaluations and imaging studies to track disease status. This study involves no investigational treatments and aims to gather data from real-world clinical practice over several years.

Age: 18Years +All Genders
11 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
P

Actively Recruiting

Researchers are building a prospective group of patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have common EGFR mutations, specifically EGFR exon 19del or exon 21 L858R. The study focuses on patients diagnosed on or after January 1, 2024, and aims to collect standardized data at key points before treatment starts, during treatment, and when treatment ends. The main goal is to observe real-world progression-free survival among those treated with first-line osimertinib. Participants may receive osimertinib combined with chemotherapy or other treatment regimens initiated after January 1, 2024, or osimertinib alone as monotherapy for newly diagnosed metastatic NSCLC. About 30% of patients enrolling before starting osimertinib will have imaging done at set intervals to monitor disease progression. Treatments are given as part of routine clinical care without experimental procedures. Throughout the study, data will be collected at baseline, during treatment, and at therapy discontinuation. Researchers will assess progression-free survival, overall survival, and time to stopping treatment, tracking these outcomes up to 100 months from treatment start. Participants are observed in a real-world setting, with no investigational drugs administered, and the study will continue until April 2029.

Age: 18Years +All Genders
10 locations
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
R

Actively Recruiting

Researchers are evaluating treatments for advanced or recurrent non-small cell lung cancer NSCLC with a specific MET exon 14 skipping gene mutation. This phase II trial compares the effects of the drug tepotinib alone versus tepotinib combined with ramucirumab. Tepotinib is a kinase inhibitor that blocks abnormal MET protein signals to slow tumor growth, while ramucirumab is an antibody that may prevent tumor blood vessel growth. Patients are randomly assigned to one of two groups one receives ramucirumab intravenously on day 1 of each 21-day cycle plus daily oral tepotinib for 21 days the other receives only daily oral tepotinib for 21 days per cycle. Treatment cycles continue unless the disease worsens or side effects become unacceptable. Optional scans and sample collections occur before and during treatment, including lymphoscintigraphy, blood and urine tests, CT scans, and MRI. Participants undergo regular assessments throughout the trial, including imaging and laboratory tests to monitor tumor response and side effects. After treatment ends, follow-up visits occur every 12 weeks until disease progression, then every 6 months for 2 years, and a final check at 3 years from randomization. Researchers measure response rates, progression-free survival, overall survival, treatment-related side effects, and duration of response.

Age: 18Minutes +All GendersPhase 2
278 locations
S

Actively Recruiting

Researchers are evaluating amivantamab-subcutaneous SC as a treatment for patients with advanced non-small cell lung cancer NSCLC that has extra copies of the MET gene, known as MET amplification. This phase II Expanded Lung-MAP treatment trial aims to assess how well amivantamab-SC works in reducing tumor growth or spread by targeting this genetic change. The study also collects tumor DNA and tissue samples to support future research. Participants receive amivantamab SC injections on days 1, 8, 15, and 22 of the first 28-day treatment cycle, followed by doses on days 1 and 15 of subsequent cycles. Treatment continues unless the cancer progresses or side effects become unacceptable. Throughout the trial, patients undergo CT or MRI scans and blood sample collections to monitor their condition and treatment effects. During the study, researchers measure the response rate to amivantamab-SC, overall survival, progression-free survival, duration of response, and side effects over up to three years. Participants are followed for up to three years after treatment ends to assess long-term outcomes. Blood samples are collected at specific times to analyze circulating tumor DNA, and a tissue and blood repository is established to support further research.

Age: 18Years +All GendersPhase 2
271 locations

1-10 of 11

1